Related Experiment Video
Updated: Feb 16, 2026

Analysis of the c-KIT Ligand Promoter Using Chromatin Immunoprecipitation
Published on: June 27, 2017
JAK-ing up the Response to KIT Inhibition
Jessica Yang1, Kimberly M Komatsubara1, Richard D Carvajal2
1Division of Hematology/Oncology, Columbia University Medical Center, New York, New York, USA.
Abstract:
Only a subset of patients with KIT-mutant melanoma derives clinical benefit from KIT inhibition, and the development of resistance is common. Efforts to improve the efficacy of KIT inhibition are limited by a lack of understanding of the mechanisms underlying response and resistance to treatment. Findings from Delyon et al. suggest that signal transducer and activator of transcription 3 activation may be an important mediator of response to nilotinib.
Related Concept Videos
The JAK-STAT Signaling Pathway
Amplifying Signals via Enzymatic Cascade
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...

